Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in CD30+ Malignant Mesothelioma
NCT03007030Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2017
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in malignant mesothelioma, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2017; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03007030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007030.